<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
      version="3.7"
      xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd">
   <titleInfo>
      <title>Using Pure Fucoidan and Radiolabeled Fucoidan (99mTc-Fucoidan) as a New Agent for Inflammation Diagnosis and Therapy</title>
   </titleInfo>
   <name type="personal" usage="primary">
      <namePart type="given">Bianca</namePart>
      <namePart type="family">Costa</namePart>
      <displayForm>Costa, Bianca</displayForm>
      <affiliation>Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro, 21941906, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Luana Barbosa</namePart>
      <namePart type="family">Correa</namePart>
      <displayForm>Correa, Luana Barbosa</displayForm>
      <affiliation>Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro, 21941906, Brazil</affiliation>
      <affiliation>National Institute for Science and Technology on Innovation on Diseases of Neglected Populations (INCT/IDPN), Oswaldo Cruz Foundation, Rio de Janeiro, 21041361, Brazil</affiliation>
      <affiliation>Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, 21041361, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Patrícia Machado</namePart>
      <namePart type="family">Rodrigues e Silva</namePart>
      <displayForm>Rodrigues e Silva, Patrícia Machado</displayForm>
      <affiliation>Laboratory of Inflammation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Yago Amigo Pinho</namePart>
      <namePart type="family">Jannini de Sá</namePart>
      <displayForm>Jannini de Sá, Yago Amigo Pinho</displayForm>
      <affiliation>Laboratory of Inflammation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Fernanda Verdini</namePart>
      <namePart type="family">Guimarães</namePart>
      <displayForm>Guimarães, Fernanda Verdini</displayForm>
      <affiliation>Laboratory of Inflammation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Luciana Magalhães Rebelo</namePart>
      <namePart type="family">Alencar</namePart>
      <displayForm>Alencar, Luciana Magalhães Rebelo</displayForm>
      <affiliation>Laboratory of Biophysics and Nanosystems, Federal University of Maranhão, Maranhão 65080-805, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Rafael Loureiro</namePart>
      <namePart type="family">Simões</namePart>
      <displayForm>Simões, Rafael Loureiro</displayForm>
      <affiliation>Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro, 21941906, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Edward</namePart>
      <namePart type="family">Helal-Neto</namePart>
      <displayForm>Helal-Neto, Edward</displayForm>
      <affiliation>Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro, 21941906, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Eduardo</namePart>
      <namePart type="family">Ricci-Junior</namePart>
      <displayForm>Ricci-Junior, Eduardo</displayForm>
      <affiliation>Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro 21941000, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Maria das Graças</namePart>
      <namePart type="family">Muller de Oliveira Henriques</namePart>
      <displayForm>Muller de Oliveira Henriques, Maria das Graças</displayForm>
      <affiliation>National Institute for Science and Technology on Innovation on Diseases of Neglected Populations (INCT/IDPN), Oswaldo Cruz Foundation, Rio de Janeiro, 21041361, Brazil</affiliation>
      <affiliation>Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, 21041361, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Elaine Cruz</namePart>
      <namePart type="family">Rosas</namePart>
      <displayForm>Rosas, Elaine Cruz</displayForm>
      <affiliation>National Institute for Science and Technology on Innovation on Diseases of Neglected Populations (INCT/IDPN), Oswaldo Cruz Foundation, Rio de Janeiro, 21041361, Brazil</affiliation>
      <affiliation>Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, 21041361, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Ralph</namePart>
      <namePart type="family">Santos-Oliveira</namePart>
      <displayForm>Santos-Oliveira, Ralph</displayForm>
      <affiliation>Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro, 21941906, Brazil</affiliation>
      <affiliation>Zona Oeste State University, Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Rio de Janeiro, 23070200, Brazil</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <typeOfResource>text</typeOfResource>
   <genre>article</genre>
   <originInfo>
      <dateIssued encoding="w3cdtf" keyDate="yes">2021</dateIssued>
   </originInfo>
   <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
      <languageTerm type="text">English</languageTerm>
   </language>
   <abstract>Inflammation is a phenomenon responsible for the perturbation of homeostasis in several levels, with many sources, such as infection, injury, and exposure to contaminants. The necessity of new products that are effective in treating inflammation processes as can selectively imaging an inflammation site is a global issue. In this study, we have evaluated the applicability of Fucoidan as a therapeutic and imaging agent. We have assessed the Fucoidan in two inflammation models for therapeutic purposes: arthritis and lungs (LPS). In the case of use as an imaging agent, we evaluated the radiolabeled Fucoidan with 99mTc in inflamed lungs (LPS). The results demonstrated that Fucoidan has a therapeutic anti-inflammatory effect, especially in the lung model (LPS). Additionally, the imaging application demonstrated that radiolabeled Fucoidan (99mTc-Fucoidan) has an important chemoattraction for inflammation sites with very high bioaccumulation, which permits to think in an imaging application. </abstract>
   <note type="admin">Pre-press version</note>
   <subject>
      <topic>Inflammation</topic>
   </subject>
   <subject>
      <topic>therapy</topic>
   </subject>
   <subject>
      <topic>radionuclide therapy, radiopharmacy</topic>
   </subject>
   <relatedItem type="host">
      <titleInfo>
         <title>Food Hydrocolloids for Health</title>
      </titleInfo>
      <originInfo>
         <publisher>Elsevier B.V.</publisher>
      </originInfo>
      <identifier type="issn">2667-0259</identifier>
      <part>
         <text type="year">2021</text>
         <extent unit="pages">
            <start>100049</start>
         </extent>
      </part>
   </relatedItem>
   <identifier type="doi">10.1016/j.fhfh.2021.100049</identifier>
   <location>
      <url>http://dx.doi.org/10.1016/j.fhfh.2021.100049</url>
   </location>
   <identifier type="pii">S2667-0259(21)00041-8</identifier>
   <accessCondition type="use and reproduction"
                    displayLabel="Creative Commons Attribution 4.0 Generic (CC BY-NC-ND 4.0)">
      <program xmlns="https://data.crossref.org/schemas/AccessIndicators.xsd">
         <licence_ref applies_to="reuse" start_date="2021-12-10"/>
         <licence_ref>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence_ref>
      </program>
   </accessCondition>
   <extension>
      <vendorName/>
      <archiveFile/>
      <originalFile>file:/C:/Users/Carlos.Martinez/OneDrive%20-%20USDA/XML_projects/OpenAccess/OpenAccess/transform/source/sourcefiles/164128545923847224-00001/2667-0259/aip/S2667025921000418/S2667025921000418.xml</originalFile>
      <workingDirectory>C:\Users\Carlos.Martinez\OneDrive - USDA\XML_projects\OpenAccess\OpenAccess\transform\result\</workingDirectory>
   </extension>
</mods>
